2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Evaluation of Ac-225-anti-VLA-4 for Targeted α-therapy for Treatment of Metastatic Melanoma

Ottawa, ON, Canada (UroToday.com) The antigen VLA4 (very late antigen 4) is expressed in the most aggressive forms of melanoma tumors. In a mouse model, Ac225-DOTA-VLA4 was injected at a dose of 3.5 MBq/nmol. An imaging agent In11-DTPA-VLA4 showed good tumor uptake but also showed significant uptake in the liver, spleen, and bone marrow.

The microdistribution was uneven in the tumor. The results showed a significant improvement in overall survival (25 days compared to 20 days with a control). The spleen uptake can potentially be reduced with blocking agents and dosage optimization. Ac225-DOTA-VLA4 shows promise for the treatment of advanced melanoma.


Presented by: Jessie Nedrow, PhD, Assistant Professor of Radiology and Radiological Science, Johns Hopkins University, Bethesda, Maryland, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada